Assignee
OCTAPHARMA AG
CH·38 granted patents·24 pending applications·192 citations·filing 1992–2025
Top patents by PatentIndex Score
62 records- 0191US7553938B2Method of providing a purified, virus safe antibody preparationOCTAPHARMA AG·Filed 2005·Granted Jun 30, 2009·56 cites·26 claims
- 0287US8769841B2Lyophilisation targeting defined residual moisture by limited desorption energy levelsOCTAPHARMA AG·Filed 2012·Granted Jul 8, 2014·17 cites·9 claims
- 0379US10640548B2Method for inactivation/removal of coagulation factors by precipitationOCTAPHARMA AG·Filed 2017·Granted May 5, 2020·3 cites·13 claims
- 0479US6518406B1Method for purification of proteinsOCTAPHARMA AG·Filed 2000·Granted Feb 11, 2003·4 cites·11 claims
- 0578US11191833B2High concentration immunoglobulin composition for pharmaceutical applicationOCTAPHARMA AG·Filed 2017·Granted Dec 7, 2021·2 cites·13 claims
- 0678US7166709B2Haemostatically active preparation containing vWF and method for the production thereofOCTAPHARMA AG·Filed 2001·Granted Jan 23, 2007·12 cites·7 claims
- 0778US5328694AStable injectable solution of factor VIIIOCTAPHARMA AG·Filed 1992·Granted Jul 12, 1994·51 cites·14 claims
- 0875US7985846B2Hemostatically active vWF-containing preparation and process for the preparation thereofOCTAPHARMA AG·Filed 2007·Granted Jul 26, 2011·2 cites·8 claims
- 0973US6893856B2Process for preparing virus-inactivated factors 1X and X by membrane chromatographyOCTAPHARMA AG·Filed 2002·Granted May 17, 2005·3 cites·17 claims
- 1071US10214575B2Process for the purification of a growth factor proteinOCTAPHARMA AG·Filed 2016·Granted Feb 26, 2019·1 cites·17 claims
- 1170US11383002B2Plasma-based films and methods for making and using the sameOCTAPHARMA AG·Filed 2020·Granted Jul 12, 2022·0 cites·15 claims
- 1269US2024002841A1Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 1369US2023374501A1Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 1465US11738069B2Polypeptides modulating SIGLEC dependent immune responsesOCTAPHARMA AG·Filed 2021·Granted Aug 29, 2023·0 cites·25 claims
- 1564US12233126B2High concentration immunoglobulin composition for pharmaceutical applicationOCTAPHARMA AG·Filed 2021·Granted Feb 25, 2025·0 cites·16 claims
- 1663US2024415945A1C1-esterase inhibitor preparationOCTAPHARMA AG·Filed 2024·Application pending·0 cites
- 1762US11383001B2Plasma-based films and methods for making and using the sameOCTAPHARMA AG·Filed 2017·Granted Jul 12, 2022·0 cites·31 claims
- 1862US9943600B2Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2014·Granted Apr 17, 2018·1 cites·11 claims
- 1962US2025177601A1Biodegradable, non-porous medical device and methods for making and using the sameOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 2059US12171808B2Glycosylated VWF fusion proteins with improved pharmacokineticsOCTAPHARMA AG·Filed 2017·Granted Dec 24, 2024·0 cites·28 claims
- 2159US2009092678A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2008·Application pending·0 cites
- 2256US12274738B2FX activation process and its use in the preparation of a FXa compositionOCTAPHARMA AG·Filed 2019·Granted Apr 15, 2025·0 cites·20 claims
- 2356US10626431B2Method for improved isolation of recombinantly produced proteinsOCTAPHARMA AG·Filed 2016·Granted Apr 21, 2020·0 cites·12 claims
- 2456US9796986B2Serum-free stable transfection and production of recombinant human proteins in human cell linesOCTAPHARMA AG·Filed 2016·Granted Oct 24, 2017·0 cites·20 claims
- 2555US11713458B2Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2017·Granted Aug 1, 2023·0 cites·11 claims
- 2655US2025144655A1Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film and method for coating a plasma-based or cryoprecipitate-based filmOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 2754US12083171B2C1-esterase inhibitor preparationOCTAPHARMA AG·Filed 2018·Granted Sep 10, 2024·0 cites·26 claims
- 2854US2007014806A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2006·Application pending·0 cites
- 2953US7700732B2Prekallikrein depleted plasma derived albumin fractionOCTAPHARMA AG·Filed 2003·Granted Apr 20, 2010·1 cites·3 claims
- 3053US2025222079A1Fx activation process and its use in the preparation of a fxa compositionOCTAPHARMA AG·Filed 2025·Application pending·0 cites
- 3152US11401300B2Process for production of fibrinogen and fibrinogen produced therebyOCTAPHARMA AG·Filed 2018·Granted Aug 2, 2022·0 cites·7 claims
- 3252US10112972B2Process for production of fibrinogen and fibrinogen produced therebyOCTAPHARMA AG·Filed 2013·Granted Oct 30, 2018·0 cites·25 claims
- 3352US2015190478A1New protecting compositions for recombinantly produced factor viiOCTAPHARMA AG·Filed 2014·Application pending·0 cites
- 3451US2019358301A1Protecting compositions for recombinantly produced factor viiiOCTAPHARMA AG·Filed 2018·Application pending·0 cites
- 3550US11013789B2Polypeptides modulating SIGLEC dependent immune responsesOCTAPHARMA AG·Filed 2017·Granted May 25, 2021·0 cites·27 claims
- 3650US2008172902A1Lyophilisation targeting defined residual moisture by limited desorption energy levelsOCTAPHARMA AG·Filed 2007·Application pending·0 cites
- 3750US2019030169A1Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2018·Application pending·0 cites
- 3850US2022305089A1Stabilizing buffer for factor viii and vwfOCTAPHARMA AG·Filed 2020·Application pending·0 cites
- 3949US6777541B2Protein purification IIOCTAPHARMA AG·Filed 2001·Granted Aug 17, 2004·0 cites·11 claims
- 4049US2015152498A1Assay and method for predicting therapeutic efficacy of immunoglobulin therapy in individual patients with relapsing remitting multiple sclerosis (rr-ms)OCTAPHARMA AG·Filed 2013·Application pending·0 cites
- 4149US2015031621A1Method for purification of complement factor hOCTAPHARMA AG·Filed 2014·Application pending·0 cites
- 4248US2016152661A1Process for isolation and purification of a target protein free of prion protein (prpsc)OCTAPHARMA AG·Filed 2015·Application pending·0 cites
- 4347US10098956B2Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2016·Granted Oct 16, 2018·0 cites·10 claims
- 4447US9938318B2Process for production of fibrinogenOCTAPHARMA AG·Filed 2016·Granted Apr 10, 2018·0 cites·11 claims
- 4546US5919909AProcess for the preparation of factor IX from biological sourcesOCTAPHARMA AG·Filed 1996·Granted Jul 6, 1999·10 cites·13 claims
- 4645US2017189494A1Protecting compositions for recombinantly produced factor viiiOCTAPHARMA AG·Filed 2017·Application pending·0 cites
- 4744US10251940B2Preparation comprising factor VIII and Von Willebrand factor peptidesOCTAPHARMA AG·Filed 2015·Granted Apr 9, 2019·0 cites·19 claims
- 4844US2015250879A1Test for hemolytic potential of pharmaceutical products and formulations for risk minimizationOCTAPHARMA AG·Filed 2013·Application pending·0 cites
- 4944US2006194300A1Process for preparing an alpha-1-antitrypsin solutionOCTAPHARMA AG·Filed 2004·Application pending·0 cites
- 5043US2002182195A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2002·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when OCTAPHARMA AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →